Realgar-Indigo Naturalis Formulation
Acute Promyelocytic Leukaemia
Instituto do Cancer do Estado de São PauloPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 95/ 100
Competitive context
19 Active assets in the Acute Promyelocytic Leukaemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytosin-Arabinosid Associazione Italiana Ematologia Oncologia Pediatrica | Phase 4 | A |
Vesanoid The Affiliated People's Hospital of Ningbo University | Phase 4 | A |
Idarubicine Technische Universität Dresden | Phase 4 | A |
Arsenic Trioxide Quetzal Therapeutics | Phase 4 | BBB |
Mitoxantrone Technische Universität Dresden | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Realgar-Indigo Naturalis Formulation is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →